Avadel Pharmaceuticals PLC expected to post a loss of 16 cents a share - Earnings Preview

Avadel Pharmaceuticals

06/08/2024 18:34

* Avadel Pharmaceuticals PLC  AVDL.OQ   AVDL.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 8 for the period ending June 30 2024
    * The Dublin-based  company is expected to report a
2,409.0% increase in revenue to $37.535 million from $1.5
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Avadel Pharmaceuticals
PLC is
for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avadel
Pharmaceuticals PLC is $23.00​, above​ its last closing price
of $16.13. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.20       -0.21      -0.30     Missed  -44.4
 Jan. 1 2024   -0.23       -0.26      -0.29     Missed  -11.8
 Jan. 1 0001   -0.38       -0.37      -0.41     Missed  -10.1​
 Jun. 30 2023  -0.38       -0.38      -0.83     Missed  -116
 ​​Jan.        -0.34       -0.38      -0.48     Missed  -27.4
 1 0001                                                 
 Dec. 31 2022  -0.30       -0.27      -0.46     Missed  -69.7​
 Sep. 30 2022  -0.21       -0.25      -0.33     Missed  -30.3
 Jun. 30 2022  -0.39       -0.41      -1.01     Missed  -146.5
 This summary was machine generated August 6 at 17:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)